Quantbot Technologies LP Makes New $617,000 Investment in HealthEquity, Inc. $HQY

Quantbot Technologies LP purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, HoldingsChannel reports. The institutional investor purchased 6,827 shares of the company’s stock, valued at approximately $617,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of HealthEquity during the 2nd quarter worth about $1,018,621,000. William Blair Investment Management LLC acquired a new stake in HealthEquity in the 4th quarter valued at about $169,956,000. Wasatch Advisors LP grew its holdings in HealthEquity by 10.5% during the second quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock worth $719,014,000 after purchasing an additional 757,801 shares during the period. Norges Bank bought a new position in HealthEquity during the fourth quarter worth about $66,927,000. Finally, Bank of New York Mellon Corp acquired a new position in HealthEquity during the second quarter worth approximately $60,177,000. Institutional investors own 99.55% of the company’s stock.

HealthEquity Stock Performance

HQY opened at $93.39 on Friday. The business has a fifty day simple moving average of $97.93 and a 200 day simple moving average of $87.81. The company has a market capitalization of $7.81 billion, a PE ratio of 34.98, a price-to-earnings-growth ratio of 1.76 and a beta of 0.21. HealthEquity, Inc. has a 1 year low of $72.76 and a 1 year high of $107.62. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.05. The firm had revenue of $350.73 million for the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The business’s revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Research analysts expect that HealthEquity, Inc. will post 3.92 EPS for the current year.

Insider Activity

In other news, EVP Michael Henry Fiore sold 2,354 shares of HealthEquity stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $95.00, for a total value of $223,630.00. Following the completion of the sale, the executive vice president directly owned 52,244 shares in the company, valued at approximately $4,963,180. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the sale, the director directly owned 62,395 shares in the company, valued at $6,527,140.95. This represents a 10.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,456 shares of company stock valued at $1,256,664 in the last quarter. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HQY. Royal Bank Of Canada raised their price objective on HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a report on Monday, June 1st. Barrington Research reaffirmed an “outperform” rating and set a $110.00 price target on shares of HealthEquity in a report on Friday, May 22nd. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a research report on Monday, June 1st. Finally, Wall Street Zen raised shares of HealthEquity from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.93.

Trending Headlines about HealthEquity

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted EPS of $1.24 versus the $1.19 consensus and revenue of $350.7 million versus $349.2 million. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved: net income rose 10% to $65.6 million, net margin expanded to 19% from 18%, and adjusted EBITDA increased 11% to $167 million, with the EBITDA margin rising to 48% from 46%. HealthEquity Reports Second Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. HSA assets reached a record $37.9 billion, supporting HealthEquity’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Neutral Sentiment: Revenue guidance was approximately $1.4 billion, broadly in line with analysts’ expectations, meaning the guidance increase was concentrated primarily in earnings rather than sales.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares worth approximately $798,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but it may still add short-term selling pressure. Adrian T. Dillon Insider Transaction
• Negative Sentiment: At roughly 35 times earnings, HQY remains priced for substantial growth. Investors may be using the strong report as an opportunity to lock in gains, particularly after the shares traded near their 52-week high.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.